ArticleTranslational vision science & technology2026
Comparative Analysis of Retinal Structure and Function in Female Carriers of Choroideremia and X-Linked Retinitis Pigmentosa.
Article in Translational vision science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To characterize and compare structural and functional outcomes in female carriers of choroideremia (CHM) and RPGR-associated X-linked retinitis pigmentosa (XLRP), focusing on differences in disease severity and progression. Methods: Carriers of CHM (n = 20) and XLRP (n = 27) were identified retrospectively from a database of a single tertiary center. Visual acuity (best-corrected visual acuity [BCVA]), multimodal imaging including color fundus photography, short-wavelength autofluorescence, optical coherence tomography (OCT), and full-field electroretinography (ERG) were analyzed. Eyes were classified into severity phenotypes using previously published grading systems. Macular retinal thicknesses were measured, and progression was assessed over follow-up. Age-matched analyses were conducted to compare CHM and XLRP carriers. Results: CHM and XLRP carriers exhibited a broad spectrum of phenotypes from subclinical changes to severe, male-like disease. In both groups, greater disease severity correlated with younger age at symptom onset, worse baseline BCVA, thinner retinochoroidal layers, and diminished light-adapted 30-Hz flicker ERG amplitudes. CHM carriers demonstrated significantly faster retinal thinning in the outer macula (3-6 mm Early Treatment Diabetic Retinopathy Study [ETDRS]) and exhibited faster BCVA decline compared to XLRP carriers (P < 0.05). Although phenotypic progression based on grading scales was infrequent, quantitative OCT measurements revealed continuous structural thinning over time. Conclusions: Compared to XLRP, CHM carriers experience accelerated retinal thinning. Severe phenotypes are associated with faster structural and functional decline. These findings underscore the need for careful monitoring and highlight female carriers as potential candidates for future gene therapy and therapeutic trials. Translational Relevance: This study translates genetic and structural disease mechanisms in X-linked retinal degeneration into clinically relevant prognostic tools that may inform counseling, surveillance, and future gene therapy strategies for female carriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.